Abvc Biopharma (ABVC) Receivables - Other (2017 - 2026)
Abvc Biopharma's (ABVC) quarterly Receivables - Other came in at $165014.0 in Q1 2026, down 69.17% YoY from $535252.0 in Q1 2025, and up 6930.85% on a QoQ basis from $2347.0 in Q4 2025.
Abvc Biopharma (ABVC) Receivables - Other (2017 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 10 years of Receivables - Other data on file, last reported at $165014.0 in Q1 2026.
- Quarterly Receivables - Other fell 69.17% year-over-year to $165014.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165014.0 (down 69.17% YoY) and the FY2025 annual result came in at $2347.0, down 99.8% from the prior year.
- Receivables - Other climbed to $165014.0 in Q1 2026, from $2347.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.4 million in Q2 2024 to a low of $2347.0 in Q4 2025.
- A 5-year average of $524155.8 and a median of $516901.5 in 2022 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2024 — Receivables - Other soared 43209.0% — and 2025, when it slumped 99.8%.
- Tracing ABVC's Receivables - Other over 5 years: stood at $513819.0 in 2022, then slumped by 99.48% to $2667.0 in 2023, then soared by 43209.0% to $1.2 million in 2024, then slumped by 99.8% to $2347.0 in 2025, then soared by 6930.85% to $165014.0 in 2026.
- The last three Receivables - Other figures came in at $165014.0 (Q1 2026), $2347.0 (Q4 2025), and $2421.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - |
| 10 | Abvc Biopharma | 24.11 Mn | 24.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36,184.00 |
| Jun 30, 2026 | 36,184.00 |
| Mar 31, 2026 | 165,014.00 |
| Mar 31, 2026 | 165,014.00 |
| Dec 31, 2025 | 2,347.00 |
| Dec 31, 2025 | 2,347.00 |
| Sep 30, 2025 | 2,421.00 |
| Sep 30, 2025 | 2,421.00 |
| Jun 30, 2025 | 1.42 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Mar 31, 2025 | 535,252.00 |
| Mar 31, 2025 | 535,252.00 |
| Dec 31, 2024 | 1.16 Mn |
| Dec 31, 2024 | 1.16 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 2,553.00 |
| Mar 31, 2024 | 2,553.00 |